Janis M. Taube

Johns Hopkins University
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (6)

Year:

2026

Year:

2026

Year:

2025

Background ADVISE (ADaptiVe biomarker trial that InformS Evolution of therapy) ( NCT03335540 ) was a biomarker-adapted feasibility clinical trial of immunohistochemistry (IHC) to inform combination immuno-oncology (I-O) treatment. Methods To inform I-O combination selection, messenger RNA expression analyses from The Cancer Genome Atlas evaluated associations between programmed death 1/programmed death ligand 1 (PD-1/PD-L1) and other I-O-associated genes. Tumor tissue blocks of melanoma, non-small cell lung cancer, renal cell carcinoma, urothelial carcinoma, squamous cell carcinoma of the head and neck, and gastroesophageal junction/gastric cancer were stained by IHC to assess expression of CD8, colony-stimulating factor 1 receptor, glucocorticoid-induced tumor necrosis factor receptor (GITR), indoleamine 2,3-dioxygenase 1, lymphocyte-activation gene 3, NKp46, forkhead box P3, and PD-L1. These results facilitated an I-O treatment selection algorithm where patient biopsy results dictated allocation into combinations of nivolumab with cabiralizumab, urelumab, linrodostat mesylate, relatlimab, BMS-986156 (anti-GITR), lirilumab, ipilimumab, or irradiation. The primary endpoint was the proportion of patients with qualified baseline tumor biopsy specimens where decision-enabling biomarker analysis was completed within 12 business days to select an I-O combination therapy. Results Correlation of PD-1/L1 and I-O-associated genes varied across the spectrum of T-cell-inflamed versus non-inflamed tumors; however, tumors with low/intermediate PD-L1 expression demonstrated distinct upregulation of immune markers grouped by cell type (T cell, macrophage, etc). IHC analyses of I-O naïve tumors corroborated these findings with distinct immune target upregulation in low-to-intermediate inflamed tumors and significant associations between IHC-detected markers and T-cell inflammation score across most markers. In the clinical trial, 20/23 (87%) of eligible patients were successfully allocated and started on treatment within the 12-day window, meeting the primary endpoint. The safety profile appeared to generally align with those reported for the individual combinations from other trials. No treatment responses occurred. Most patients were allocated to the cabiralizumab treatment arm. Conclusions Actualization of a patient-specific I-O combination treatment selection strategy is feasible, however, determination of de novo integral biomarker thresholds of novel I-O targets to facilitate effective treatment of PD-1-refractory cancer remains fraught. These data emphasize the difficulty of integral biomarker development for I-O in translating from immunotherapy treatment-naïve biospecimens to the selection of patients in the PD-1-refractory state. Trial registration number NCT03335540 .

Year:

2025

Purpose: Co-mutations of the Kirsten rat sarcoma virus ( KRAS ) and serine / threonine kinase 11 ( STK11 ) genes in advanced non–small cell lung cancer (NSCLC) are associated with immune checkpoint blockade (ICB) resistance. Although neoadjuvant chemoimmunotherapy is now a standard-of-care treatment for resectable NSCLC, the clinical and immunologic impacts of KRAS and STK11 co-mutations in this setting are unknown. Experimental Design: We evaluated and compared recurrence-free survival of resectable KRAS -mutated NSCLC tumors, with or without co-occurring STK11 mutations, treated with neoadjuvant ICB. Single-cell transcriptomics was performed on tumor-infiltrating T cells from seven KRAS mut /STK11 wt tumors and six KRAS and STK11 co-mutated ( KRAS mut /STK11 mut ) tumors. Results: Relative to KRAS mut /STK11 wt tumors, KRAS mut /STK11 mut exhibited significantly higher recurrence risk. Single-cell transcriptomics showed enhanced oxidative phosphorylation with evidence of decreased prostaglandin E2 signaling and increased IL-2 signaling in CD8 + tumor-infiltrating lymphocytes (TIL) from KRAS mut /STK11 mut tumors, a finding that was mirrored in KRAS wt tumors that relapsed. TILs from KRAS mut /STK11 mut tumors expressed high levels of molecules associated with tumor residence, including CD39 and ZNF683 (HOBIT). Conclusions: These divergent T-cell transcriptional fates suggest that T-cell maintenance and residence may be detrimental to antitumor immunity in the context of neoadjuvant ICB for resectable NSCLC, regardless of KRAS mutation status. Our work provides a basis for future investigations into the mechanisms underpinning prostaglandin E2 signaling and IL-2 signaling as they relate to T-cell immunity to cancer and to divergent clinical outcomes in KRAS mut /STK11 mut NSCLC treated with neoadjuvant ICB.

Year:

2025

Astronomy was among the first disciplines to embrace Big Data and use it to characterize spatial relationships between stars and galaxies. Today, medicine, in particular pathology, has similar needs with regard to characterizing the spatial relationships between cells, with an emphasis on understanding the organization of the tumor microenvironment. In this article, we chronicle the emergence of data-intensive science through the development of the Sloan Digital Sky Survey and describe how analysis patterns and approaches similarly apply to multiplex immunofluorescence (mIF) pathology image exploration. The lessons learned from astronomy are detailed, and the new AstroPath platform that capitalizes on these learnings is described. AstroPath is being used to generate and display tumor-immune maps that can be used for mIF immuno-oncology biomarker development. The development of AstroPath as an open resource for visualizing and analyzing large-scale spatially resolved mIF datasets is underway, akin to how publicly available maps of the sky have been used by astronomers and citizen scientists alike. Associated technical, academic, and funding considerations, as well as extended future development for inclusion of spatial transcriptomics and application of artificial intelligence, are also addressed.

Year:

2022

Collaborators (11)

caroline robert

- Directeur de l’équipe «Résistance thérapeutique» dans l’Unité INSERM U 981 : Biomarqueurs prédicteurs et nouvelles stratégies moléculaires en thérapeutique anticancéreuse

Université de Paris Faculté de Santé

FRANCE
View details

Joshua Reuss

Assistant Professor of Medicine

-

UNITED STATES
View details

Hongkai Ji

Professor

Johns Hopkins University Bloomberg School of Public Health

UNITED STATES
View details

Khaled Sanber

Assistant Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Zhicheng Ji

Assistant Professor

Duke University School of Medicine

UNITED STATES
View details

Valsamo Anagnostou

Alex Grass Professor of Oncology

Johns Hopkins University School of Medicine

UNITED STATES
View details

Tianbei Zhang

Johns Hopkins University

UNITED STATES
View details

Patrick M. Forde

Trinity College Dublin

IRELAND
View details

Céleste Lebbé

Université Paris Cité

FRANCE
View details

Jonathan Spicer

Professor of Surgery

McGill University

CANADA
View details

Drew Pardoll

Professor

Johns Hopkins University

UNITED STATES
View details